BioNTech SE
NASDAQ:BNTX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
78.36
124.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
BioNTech SE
BioNTech SE
Total Current Assets
BioNTech SE
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BioNTech SE
NASDAQ:BNTX
|
Total Current Assets
€19.5B
|
CAGR 3-Years
127%
|
CAGR 5-Years
113%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Total Current Assets
€675m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
|
CureVac NV
NASDAQ:CVAC
|
Total Current Assets
€478.4m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Total Current Assets
€449.4m
|
CAGR 3-Years
23%
|
CAGR 5-Years
227%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Total Current Assets
€704.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Formycon AG
XETRA:FYB
|
Total Current Assets
€67.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
BioNTech SE
Glance View
BioNTech SE, founded in 2008 and headquartered in Mainz, Germany, is a pioneering biotechnology company that has rapidly garnered global attention for its innovative approach to vaccine development and personalized cancer therapies. Originally focused on harnessing the power of messenger RNA (mRNA) technology, BioNTech became a household name following its collaboration with Pfizer to develop one of the first COVID-19 vaccines. This partnership not only showcased the potential of mRNA technology in combatting infectious diseases but also underscored the company’s agility in responding to urgent global health challenges. With its robust pipeline of therapeutics spanning infectious diseases and oncology, BioNTech is positioning itself as a leader in the emerging field of immuno-oncology, aiming to harness the body's immune system to fight cancer more effectively. For investors, BioNTech represents a unique opportunity in the biotech sector, characterized by its strong innovation pipeline, strategic partnerships, and a solid financial footing bolstered by revenues from its COVID-19 vaccine. The company's focus on research and development, with aims to expand its therapeutic offerings beyond infectious diseases to targeted cancer treatments, indicates significant growth potential. Furthermore, as a company driven by science and a commitment to patient-centric solutions, BioNTech is well-positioned to benefit from ongoing advancements in biotechnology and the increasing demand for personalized medicine. With a proven track record and ambitious future aspirations, BioNTech SE offers a compelling narrative for investors looking to capitalize on the transformative potential of biotechnology.
See Also
What is BioNTech SE's Total Current Assets?
Total Current Assets
19.5B
EUR
Based on the financial report for Dec 31, 2023, BioNTech SE's Total Current Assets amounts to 19.5B EUR.
What is BioNTech SE's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
113%
Over the last year, the Total Current Assets growth was -11%. The average annual Total Current Assets growth rates for BioNTech SE have been 127% over the past three years , 113% over the past five years .
You don't have any saved screeners yet
